These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 17295433)

  • 21. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
    Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
    Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab-induced serum sickness in multiple sclerosis patients.
    Wolf AB; Ryerson LZ; Pandey K; McGettigan BM; Vollmer T; Corboy JR; Alvarez E
    Mult Scler Relat Disord; 2019 Nov; 36():101402. PubMed ID: 31542710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Desensitization protocol for rituximab-induced serum sickness.
    Fajt ML; Petrov AA
    Curr Drug Saf; 2014; 9(3):240-2. PubMed ID: 24861993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum sickness and severe angioedema following rituximab therapy in RA.
    Kumar A; Khamkar K; Gopal H
    Int J Rheum Dis; 2012 Feb; 15(1):e6-7. PubMed ID: 22324965
    [No Abstract]   [Full Text] [Related]  

  • 26. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
    Faurschou A; Gniadecki R
    Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interstitial pneumonitis related to rituximab therapy.
    Burton C; Kaczmarski R; Jan-Mohamed R
    N Engl J Med; 2003 Jun; 348(26):2690-1; discussion 2690-1. PubMed ID: 12826649
    [No Abstract]   [Full Text] [Related]  

  • 28. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab for myasthenia gravis: three case reports and review of the literature.
    Stieglbauer K; Topakian R; Schäffer V; Aichner FT
    J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab-induced vasculitis: A case report and review of the medical published work.
    Kim MJ; Kim HO; Kim HY; Park YM
    J Dermatol; 2009 May; 36(5):284-7. PubMed ID: 19382999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab-induced acute severe thrombocytopenia.
    Parajuli R; Hire E; Shah BK
    Br J Haematol; 2010 Jun; 149(6):804. PubMed ID: 20602622
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
    Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE
    J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment.
    Hellerstedt B; Ahmed A
    Ann Oncol; 2003 Dec; 14(12):1792. PubMed ID: 14630688
    [No Abstract]   [Full Text] [Related]  

  • 35. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
    Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum sickness secondary to ciprofloxacin use.
    Guharoy SR
    Vet Hum Toxicol; 1994 Dec; 36(6):540-1. PubMed ID: 7900274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN; Masding A; Somerville M; Gaffney K; Scott DG
    Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.